Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.59 |
| ▸ | MAPKAPK5 | Q8IW41 | 18/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 17/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 16/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16280026 | 1.00 | MAPKAPK2 (0.59) | MAPKAPK2MAPKAPK5MAPK14MAPK1 | |
| SCHEMBL30514471 | 0.91 | MAPKAPK2 (0.49) | MAPKAPK2MAPKAPK5MAPK14MAPK1 | |
| SCHEMBL16280470 | 0.91 | MAPKAPK2 (0.49) | MAPKAPK2MAPKAPK5MAPK14MAPK1 | |
| SCHEMBL30514460 | 0.90 | MAPKAPK2 (0.61) | MAPKAPK2MAPKAPK5MAPK14MAPK1 | |
| SCHEMBL16280155 | 0.90 | MAPKAPK2 (0.61) | MAPKAPK2MAPKAPK5MAPK14MAPK1 | |
| SCHEMBL16280388 | 0.89 | MAPKAPK2 (0.67) | MAPKAPK2MAPKAPK5MAPK14MAPK1 | |
| SCHEMBL30514510 | 0.89 | MAPKAPK2 (0.67) | MAPKAPK2MAPKAPK5MAPK14MAPK1 | |
| SCHEMBL16280091 | 0.89 | MAPKAPK5 (0.55) | MAPKAPK2MAPKAPK5MAPK14MAPK1 | |
| SCHEMBL16280227 | 0.89 | MAPKAPK5 (0.55) | MAPKAPK2MAPKAPK5MAPK14MAPK1 | |
| SCHEMBL30514472 | 0.89 | MAPKAPK5 (0.55) | MAPKAPK2MAPKAPK5MAPK14MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12616696-B2 | Crystalline forms of (p)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2′-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5′,6-dimethyl-2h-[1,4′-bipyridin]-2-one | ACLARIS THERAPEUTICS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20230242505-A1 | PROCESS, COMPOSITIONS, AND CRYSTALLINE FORMS OF SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242505-A1 | PROCESS, COMPOSITIONS, AND CRYSTALLINE FORMS OF SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | MAPK6, MAPK1, MAPK8 | MAPKAPK2 44/4885MAPKAPK5 47/4885MAPK14 38/4885 |
| US-12616696-B2 | Crystalline forms of (p)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2′-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5′,6-dimethyl-2h-[1,4′-bipyridin]-2-one | MALT1, SSB, BCL9 | MAPKAPK2 2610/4885MAPKAPK5 3641/4885MAPK14 3707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.